The Medicine Maker
  • Explore

    Explore

    • Latest
    • Features
    • Interviews
    • Business & Trends
    • Technology & Manufacturing
    • Product Profiles
    • White Papers

    Featured Topics

    • Biopharma
    • Small Molecules
    • Cell & Gene
    • Future of Pharma

    Issues

    • Latest Issue
    • Archive
    • Cell and Gene Therapy Supplement
  • Topics

    Topics

    • Cell & Gene
    • Bioprocessing
    • Drug Delivery
    • Drug Discovery
    • Development & Clinical
    • Formulation
    • Facilities & Equipment
    • Outsourcing
    • Packaging
    • Regulation & Standards
    • Small Molecules
    • Supply Chain
  • News & Blogs

    News & Blogs

    • Industry News
    • Research News
    • Blogs
  • Events
    • Live Events
    • Webinars
  • Community & Awards

    Community & Awards

    • Power List
    • Sitting Down With
    • Innovation Awards
    • Company of the Year Awards
    • Authors & Contributors
  • Multimedia
    • Video
    • eBooks
    • Content Hubs
Subscribe
Subscribe
The Medicine Maker / Issues / 2017 / Apr / Making the Media of the Future – Today
Manufacture Bioprocessing Biopharma Sponsored

Making the Media of the Future – Today

Biopharma manufacturing continues to advance and the demand for new innovations, such as more efficient cell culture media, is constant.Biopharma manufacturing continues to advance and the demand for new innovations, such as more efficient cell culture media, is constant.

04/21/2017 1 min read

Share

In previous articles in this series, we heard about intensified perfusion systems from Delia Lyons (1), and about high-density cryopreservation from Jochen Sieck (2). Now, Lyons is joined by Jeremiah Riesberg (Senior Scientist, Perfusion Medium Development, Millipore Sigma, USA) to discuss a novel culture medium. The product, currently in beta testing with chosen clients, has been designed for the most challenging of applications – intensified perfusion at steady state – but is also applicable to a range of other processes.

Figure 1: Final medium (M3) could maintain a target cell density with a 40pL/cell/d with a 50 percent increase in specific productivity compared to prototype M1.

Newsletters

Receive the latest pharmaceutical news, personalities, education, and career development – weekly to your inbox.

Newsletter Signup Image

References

  1. D Lyons, “An Intense Focus on Perfusion”, The Medicine Maker, 27 (2017). Available at: http://bit.ly/2mF5Dqp. JB Sieck, “Freezing Down Time in Bioprocessing”, The Medicine Maker, 28 (2017). Available at: http://bit.ly/2nK7wzD.

Recommended

Related Content

The Mindset for Success in Biopharma's New Multipolar World
Biopharma Development & Clinical Outsourcing
The Mindset for Success in Biopharma's New Multipolar World

August 18, 2026

10 min read

From collapsing legacy models to the rise of Chinese biotech, industry leaders are being forced to rethink how drugs are developed, funded, and brought to market

Biopharma Labs Have an Integration Debt Problem
Biopharma Technology & Manufacturing
Biopharma Labs Have an Integration Debt Problem

August 17, 2026

5 min read

Biopharma labs are investing heavily in digital tools, but without trusted data architecture, each new platform can add another point of failure

Musings from The Power List: Ali Pashazadeh
Outsourcing Biopharma Business & Trends
Musings from The Power List: Ali Pashazadeh

August 7, 2026

7 min read

Ali Pashazadeh argues that management failures sink too many clinical programs – and explains why commercial discipline must start much earlier

Moving Glycosylation Control Upstream
Biopharma Interviews Technology & Manufacturing
Moving Glycosylation Control Upstream

August 6, 2026

7 min read

Samsung Biologics’ Sojeong Lee discusses why biologics developers are paying closer attention to glycosylation earlier in development.

The Medicine Maker
Subscribe

About

  • About Us
  • Work at Conexiant Europe
  • Terms and Conditions
  • Privacy Policy
  • Advertise With Us
  • Contact Us

Copyright © 2026 Texere Publishing Limited (trading as Conexiant), with registered number 08113419 whose registered office is at Booths No. 1, Booths Park, Chelford Road, Knutsford, England, WA16 8GS.

Affiliations:

Specialties:

Areas of Expertise:

Contributions: